Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion

doi:10.1038/srep39355

CORC > 兰州大学 > 兰州大学 > 公共卫生学院 > 期刊论文

	Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion
	Rong, BX; Pan, H; Gao, WL; Yang, SY; Rong, BX (reprint author), Xian Med Univ, Affiliated Hosp 1, Dept Resp Med, Xian, Peoples R China.; Rong, BX (reprint author), Res Ctr Prevent & Treatment Resp Dis, Xian 710077, Shaanxi Provinc, Peoples R China.
刊名	SCIENTIFIC REPORTS
	2016-12-15
卷号	6
ISSN号	2045-2322
DOI	10.1038/srep39355
文献子类	Article
英文摘要	A certain number of studies have showed that p53 gene transfer has an anti-tumor activity in vitro and in vivo. This study was to evaluate the efficacy and safety of thoracic perfusion of recombinant human adenovirus p53 (rAd-p53, Gendicine) for controlling malignant pleural effusion (MPE). We searched for the relevant studies from the database of MEDLINE, Web of Science, EMBASE, Cochrance Library and CNKI to collect the trials concerning the efficacy and safety of rAd-p53 to treat MPE. Fourteen randomised controlled trials (RCTs) with 879 patients were involved in this analysis. The rAd-p53 combined with chemotherapeutic agents significantly improved the overall response rate (ORR) (P < 0.001; odds ratio = 3.73) and disease control rate (DCR) (P < 0.001; odds ratio = 2.32) of patients with MPE as well as the quality of life (QOL) of patients (P < 0.001; odds ratio = 4.27), compared with that of chemotherapeutic agents alone. In addition, the participation of rAd-p53 did not have an obvious impact on the most of incidence of adverse reactions (AEs) (P < 0.05) except the fever (P < 0.001). However, the fever was self-limited and could be tolerated well. The application of rAd-p53 through thoracic perfusion for treating MPE had a better efficacy and safety, which could be a potential choice for controlling MPE.
学科主题	Science & Technology - Other Topics
出版地	LONDON
语种	英语
WOS记录号	WOS:000390280800001
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/189121]
专题	公共卫生学院_期刊论文
通讯作者	Rong, BX (reprint author), Xian Med Univ, Affiliated Hosp 1, Dept Resp Med, Xian, Peoples R China.; Rong, BX (reprint author), Res Ctr Prevent & Treatment Resp Dis, Xian 710077, Shaanxi Provinc, Peoples R China.
推荐引用方式 GB/T 7714	Rong, BX,Pan, H,Gao, WL,et al. Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion[J]. SCIENTIFIC REPORTS,2016,6.
APA	Rong, BX,Pan, H,Gao, WL,Yang, SY,Rong, BX ,&Rong, BX .(2016).Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion.SCIENTIFIC REPORTS,6.
MLA	Rong, BX,et al."Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion".SCIENTIFIC REPORTS 6(2016).